Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.BTX · Entity 8278 | Director | December 08, 2021 | December 11, 2021 |
| IN8BIO, INC.INAB · Entity 7941 | Director | May 09, 2026 | May 12, 2026 |
| Traws Pharma, Inc.TRAW · Entity 8032 | Director | September 16, 2024 | September 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date December 08, 2021 · Filed December 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2031-12-07 | Direct | 67,000 |
Reported balance
After 2021-12-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-08 · Grant · Acquired 67,000 · Balance 67,000 F1: A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date.
IN8BIO, INC.
Report date May 09, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-05-09 | Direct | 22,000 |
Reported balance
After 2026-05-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-09 · Grant · Acquired 22,000 · Balance 22,000 F1: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
Traws Pharma, Inc.
Report date September 16, 2024 · Filed September 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2034-09-16 | Direct | 164,000 |
Reported balance
After 2024-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-16 · Grant · Acquired 164,000 · Balance 164,000 F1: These options vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2026 Filed May 12, 2026 20:30 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001853815-26-000002 · form4-05122026_040512.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-09 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 63,150 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001415889-25-012654 · form4-05122025_040520.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,150 Underlying: Common Stock · 63,150 shares Expires 2035-05-08 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 39,449 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-24-030064 · form4-12232024_041218.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,449 Underlying: Common Stock · 39,449 shares Expires 2034-12-19 F1 · derivative.exercise_date: The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:12 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (Right to Purchase) · Derivative | 164,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0000929638-24-003160 · form4.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2034-09-16 F1 · derivative.exercise_date: These options vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 21:00 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 33,650 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001415889-24-016969 · form4-06142024_050614.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,650 Underlying: Common Stock · 33,650 shares Expires 2034-06-12 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 23:44 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-038121 · doc4.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:09 UTC | IN8BIO, INC. INAB · Entity 7941 | PurchaseCommon Stock | 526 | $1.90 | $999.40 |
DisclosureSEC source: 0001209191-22-046601 · doc4.xml · nonDerivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,826 Read SEC document |
| June 01, 2022 Filed Jun 14, 2022 23:03 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-22-036803 · doc4.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 1, 2022 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 01, 2022 Filed Sep 23, 2022 21:07 UTC Amendment | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-22-051161 · doc4a.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2032-06-01 F1 · shares: The original Form 4 inadvertently listed the incorrect number of shares granted to the Reporting Person. F2 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 1, 2022 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. F1 · derivative.underlying_shares: The original Form 4 inadvertently listed the incorrect number of shares granted to the Reporting Person. F1 · balance_after: The original Form 4 inadvertently listed the incorrect number of shares granted to the Reporting Person. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:00 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option · Derivative | 67,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001140361-21-041287 · form4.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 01:28 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049155 · doc4.xml · derivative · entry 1 Greenwood Luba · CIK 0001853815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on July 22, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.